Profile data is unavailable for this security.
About the company
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules such as specialty chemicals, vitamins and chemicals, and disinfectants. Its segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. The Marketable Molecules segment manufactures and supplies intermediates, quaternary compounds, specialty chemicals, and various products for pharmaceuticals and cosmetics. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom, and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., and others.
- Revenue in INR (TTM)27.97bn
- Net income in INR1.19bn
- Incorporated2007
- Employees1.11k
- LocationDishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
- Phone+91 2 717420100
- Fax+91 7 926420198
- Websitehttps://www.carbogen-amcis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories Ltd | 17.87bn | 994.48m | 20.82bn | 1.81k | 20.93 | -- | 14.12 | 1.17 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Panacea Biotec Ltd | 6.06bn | -77.80m | 21.24bn | 1.29k | -- | -- | 84.45 | 3.51 | -1.27 | -1.27 | 98.66 | -- | -- | -- | -- | 4,694,217.00 | -- | 13.08 | -- | 19.61 | 57.70 | 48.06 | -1.35 | 30.99 | -- | -11.50 | -- | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 21.64bn | 1.78k | -- | -- | 27.45 | 1.72 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 22.27bn | 1.16bn | 21.95bn | 2.89k | 18.93 | -- | 11.29 | 0.9853 | 3.95 | 3.95 | 75.87 | -- | -- | -- | -- | 7,704,566.00 | -- | 10.26 | -- | 13.42 | 34.42 | 32.57 | 5.20 | 9.33 | -- | 10.46 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 23.48bn | 966.00 | 21.80 | -- | 15.95 | 2.70 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Hikal Ltd | 17.46bn | -130.00m | 25.85bn | 2.06k | -- | -- | 17.64 | 1.48 | -1.05 | -1.05 | 141.83 | -- | -- | -- | -- | 8,465,567.00 | -- | 4.78 | -- | 7.00 | 55.47 | 48.00 | -0.7447 | 5.71 | -- | 1.21 | -- | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 25.89bn | 3.33k | 8.80 | -- | 6.18 | 1.17 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Gufic BioSciences Ltd | 8.74bn | 569.19m | 29.38bn | 1.99k | 51.60 | 4.66 | 34.62 | 3.36 | 5.68 | 5.68 | 87.10 | 62.94 | 0.7354 | 1.87 | 2.75 | 4,394,322.00 | 4.79 | 10.27 | 7.34 | 16.11 | 55.47 | 46.41 | 6.52 | 10.48 | 1.06 | 3.13 | 0.3691 | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| Dishman Carbogen Amcis Ltd | 27.97bn | 1.19bn | 30.82bn | 1.11k | 25.96 | -- | 6.88 | 1.10 | 7.57 | 7.57 | 178.50 | -- | -- | -- | -- | 25,287,880.00 | -- | -0.7247 | -- | -0.9005 | 84.96 | 74.27 | 4.25 | -2.77 | -- | 1.31 | -- | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| SMS Pharmaceuticals Ltd | 8.97bn | 895.91m | 31.86bn | 1.47k | 33.59 | -- | 25.38 | 3.55 | 10.13 | 10.13 | 101.51 | -- | -- | -- | -- | 6,102,851.00 | -- | 5.58 | -- | 7.66 | 32.55 | 33.78 | 9.71 | 8.05 | -- | 5.85 | -- | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| RPG Life Sciences Ltd | 6.74bn | 2.03bn | 32.45bn | 1.33k | 16.02 | -- | 14.51 | 4.82 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Orchid Pharma Ltd | 8.11bn | 188.68m | 33.67bn | 737.00 | 178.55 | -- | 63.75 | 4.15 | 3.72 | 3.72 | 160.07 | -- | -- | -- | -- | 11,006,770.00 | -- | 1.40 | -- | 1.72 | 36.82 | 35.89 | 2.14 | 2.75 | -- | 0.4822 | -- | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| Aarti Drugs Ltd | 25.22bn | 2.03bn | 33.94bn | 1.28k | 16.85 | -- | 12.75 | 1.35 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| Gujarat Themis Biosyn Ltd | 1.59bn | 477.88m | 34.47bn | 221.00 | 72.13 | -- | 59.55 | 21.64 | 4.39 | 4.39 | 14.62 | -- | -- | -- | -- | 7,209,322.00 | -- | 30.70 | -- | 34.37 | 62.78 | 68.03 | 29.99 | 35.51 | -- | 55.73 | -- | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
| Senores Pharmaceuticals Ltd | 5.89bn | 1.02bn | 36.56bn | 194.00 | 35.42 | -- | 28.11 | 6.21 | 22.41 | 22.41 | 130.31 | -- | -- | -- | -- | 30,336,080.00 | -- | -- | -- | -- | 58.73 | -- | 17.48 | -- | -- | 5.94 | -- | -- | 85.64 | -- | 86.17 | -- | -- | -- |
| Innova Captab Ltd | 14.97bn | 1.32bn | 38.50bn | 1.95k | 29.08 | -- | 21.87 | 2.57 | 23.13 | 23.13 | 261.52 | -- | -- | -- | -- | 7,676,703.00 | -- | 10.02 | -- | 15.00 | 36.26 | 27.20 | 8.85 | 8.72 | -- | 12.45 | -- | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
Data as of Feb 17 2026. Currency figures normalised to Dishman Carbogen Amcis Ltd's reporting currency: Indian Rupee INR
4.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 31 Dec 2025 | 3.43m | 2.19% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 1.54m | 0.98% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 Dec 2025 | 1.48m | 0.94% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 301.21k | 0.19% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 222.03k | 0.14% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 167.45k | 0.11% |
| Connor, Clark & Lunn Investment Management Ltd.as of 30 Jan 2026 | 111.56k | 0.07% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 71.39k | 0.05% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2025 | 38.76k | 0.03% |
| DFA Australia Ltd.as of 31 Dec 2025 | 16.73k | 0.01% |
More ▼
Data from 30 Jun 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
